BioNTech said it would invest some of the profits from the Covid-19 vaccine it markets with Pfizer into developing shots for malaria and tuberculosis in Africa, part of the company’s plan to establish a production hub for innovative medicines
BioNTech SE said it would invest some of the profits from the Covid-19 vaccine it markets with Pfizer Inc. into developing shots for malaria and tuberculosis in Africa, part of the German company’s plan to establish a large production hub for innovative medicines on the continent.
The company’s new venture aims to produce a highly effective mRNA vaccine with durable protective immunity to prevent and eventually eradicate malaria, he said.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
WSJ News Exclusive | Covid-19 Immunity Wanes, but Third Shot Still Rarely Needed, BioNTech CEO SaysCovid-19 immunity wanes in people fully vaccinated with the Pfizer-BioNTech shot, but most still won’t need a third dose, the CEO of BioNTech said
Consulte Mais informação »
Outbreaks of covid-19 leave South-East Asia with little policy roomOn July 20th the Asian Development Bank pared back its growth forecasts for South-East Asia. It now expects an expansion of 4% this year, compared with an earlier forecast of 4.4%
Consulte Mais informação »
Leopardo de las nieves Ramil tiene COVID-19 en el Zoo de San DiegoEl personal del zoológico está investigando cómo se infectó
Consulte Mais informação »
Covid-19 Vaccine Holdouts Face Restrictions in Europe as Delta Variant SpreadsWorried about the rapid spread of the Delta variant, governments are nudging, and in some cases, pushing, people to get vaccinated by introducing restrictions to daily life for those without a Covid-19 shot.
Consulte Mais informação »
WSJ News Exclusive | Covid-19 Pill Race Heats Up as Japanese Firm Vies With Pfizer, MerckJapan’s Shionogi has started human trials for a once-a-day drug designed to neutralize the coronavirus in less than a week as Pfizer and Merck carry out later-stage tests.
Consulte Mais informação »